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ABSTRACT  
New water soluble, enantiopure arene ruthenium compound SRuSN-(1R,4S)-[(
6
-p-
cymene)Ru{ĸNH(Bn),ĸNOH}Cl]Cl (Bn = benzyl, 1a’) has been synthesized. The novel 
compound along with that previously described RRuRN-(1S,4R)-[(
6
-p-
cymene)Ru{ĸNH(Bn),ĸNOH}Cl]Cl (1a) was evaluated by polarimetry, ultra-violet and 
circular dichroism spectroscopy. The structure of novel ruthenium derivative 1a’ was 
determined by single crystal X-ray crystallography. Both enantiomers have been tested 
against several cancer cell lines in vitro: prostate PC-3, lung A-549, pancreas MIA 
PaCa-2, colorectal HCT-116, leukemia Jurkat and cervical HeLa. Both enantiomers are 
active and versatile cytotoxic agents, showing IC50 values from 2 to 12 times lower than 
those found for cisplatin in the different cell lines evaluated. The mechanism of cell 
death induced by the metal compounds was analyzed in A-549 and Jurkat cell lines. 
Derivatives 1a and 1a’ induced apoptotic cell death of A-549 cells while dose-
dependent cell death mechanisms have been found in the Jurkat cell line. Compound-
DNA interactions have been investigated by equilibrium dialysis, Fluorescence 
Resonance Energy Transfer (FRET) melting assays and viscometric titrations, 
revealing moderate binding affinity of 1a and 1a’ towards duplex DNA. Finally, the 
efficacy of 1a in a preliminary in vivo assay of PC-3 xenografts in nude mice has been 
evaluated, resulting in a promising inhibition of tumor growth by 45%. Analysis of 
tumor tissue also showed a significant decrease of levels of crucial molecules in the 
invasive phenotype of PC-3 cells.  
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1. Introduction 
 Although cisplatin and its derivatives are widely used in the clinic, platinum-based 
compounds possess various problems as anticancer drugs such as high levels of in vivo 
toxicity, drug resistance and poor aqueous solubility [1]. The development of anti-
cancer metal drug candidates to overcome those disadvantages has produced a plethora 
of possible chemotherapeutics [2-9]. Ruthenium compounds are among the most 
promising candidates with currently KP1339 (sodium trans-[tetrachloridobis(1H-
indazole)-ruthenate(III)]) and NAMI-A (imidazolium trans-
[tetrachloridobis(dimethylsulfoxide)(1H-imidazole)-ruthenate(III)]) having entered 
clinical trials [8,10-13]. Another promising class of antitumor ruthenium-based 
compounds are the arene ruthenium RAPTA derivatives, with RAPTA-C ([(6-p-
cymene)Ru(pta)Cl2], pta = 1,3,5-triaza-7-phosphatricyclo[3.3.1]decane) in advanced 
pre-clinical studies [14,15].  
The effect of stereochemistry on biological activity is of great importance in 
medicinal chemistry, as many of the biological targets are chiral [16-20]. About more 
than half of the drugs currently in clinical use are chiral compounds, marketed as 
racemates or as single enantiomers. The anticancer properties of chiral metal derivatives 
have been largely explored [21-36], but the role of the stereochemistry in the biological 
activity of non-platinum based compounds has been less investigated [18-20,37-48]. 
From those enantiomers isolated and studied, different antitumor activities by factors of 
2-6 have been found for ruthenium [19,37,41,44,48], osmium [20], and titanium 
[17,40,45,46] compounds. Thus, Manna et al [17] proposed that stereochemistry should 
be considered in the design, modification, and improvement of active compounds. 
Oxime groups offer significant advantages for biological application. They possess 
stronger hydrogen–bonding abilities than alcohols or carboxylic acids and thus, they can 
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favor solubility of the resulting compounds in biological media [49]. In addition, some 
oxime organic derivatives have been reported to have anticancer properties [50,51]. 
Oxime-containing Pt(II), Rh(III), Ir(III) and Ru(II) compounds with antitumoral 
properties reported to date have shown strong anticancer activities whereas the 
compounds do not interact with DNA in a similar way to cisplatin [52-57]. This fact 
opens the gate to the discovering of therapeutic anticancer drugs with different 
mechanisms of action than those of cisplatin and derivatives [58,59].  
Studies of enantiopure arene ruthenium anticancer derivatives are scarce [19,20,48], 
probably due to the difficult isolation of unique stereoisomers of such organometallic 
compounds [22,60]. Recently, a Noyori-like arene Ru(II) catalyst have shown a broad 
range of potent anticancer activities [48]. Other enantiopure, chiral-at-metal arene group 
8 compounds that have demonstrated high cytotoxic profiles are the Os(II) 
iminopyridine halide enantiomers of general formula [{(η6-p-cymene)Os(ImpyMe)I]PF6 
(ImpyMe = N-(2-pyridylmethylene)-1-phenylethylamine) [20]. Optically active RAPTA 
analogues have been also studied showing good cytotoxic potency against human 
ovarian carcinoma A-278 cells [19]. 
We have recently reported an optically active p-cymene ruthenium(II) compound with 
an amino-oxime ligand derived from R-limonene, of formula RRuRN-(1S,4R)-[(
6
-p-
cymene)Ru{ĸNH(Bn),ĸNOH}Cl]Cl (Bn = benzyl, 1a) (Fig. 1), which possess relevant 
antitumor properties. Our compound shows high solubility in water and significant 
effects on cytotoxicity, cell adhesion to collagen and migration of androgen-
independent prostate PC-3 cancer cells while it does not seem to exhibit strong 
interactions with plasmid DNA by electrophoretic mobility shift assays and Calf 
Thymus (CT) DNA thermal denaturing experiments [61].  
FIGURE 1 
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Encouraged by our previous results, we decided to explore the reactions of [(6-p-
cymene)RuCl2]2 with the amino-oxime chiral organic compound (1R,4S)-
{NOH,(Bn)NH} (a’, see Fig. 2) [62,63], derived from S-limonene. This naturally 
occurring terpene is an inexpensive starting reagent, commercially available in an 
optically pure form and easily tailored by stereoselective functionalization [64,65].  
We report here on the synthesis and characterization of the novel Ru(II) enantiomer 
SRuSN-(1R,4S)-[(
6
-p-cymene)Ru{ĸNH(Bn),ĸNOH}Cl]Cl (1a’). The new compound 
along with that previously described, 1a, have been evaluated against several cancer cell 
lines in vitro: prostate PC-3, lung A-549, pancreas MIA PaCa-2, colorectal HCT-116, 
leukemia Jurkat and cervical HeLa. The mechanism of cell death induced by these 
ruthenium complexes was analyzed in A-549 and Jurkat cell lines. DNA interactions of 
both enantiomers have been investigated by Fluorescence Resonance Energy Transfer 
(FRET) melting assays, dialysis and viscometric titrations experiments. Additionally, 
we describe the efficacy of 1a in an in vivo evaluation of PC-3 xenografts in nude mice. 
 
2. Experimental Section  
2.1. Chemicals and synthesis  
Synthesis of ruthenium complexes 1a and 1a’ were performed without exclusion of 
moisture or air. Solvents were dried by known procedures and used freshly distilled. 
(1S,4R)-, (1R,4S)-[NH(Bn),NOH] (a, a’) and corresponding adducts (1S,4R)-, (1R,4S)-
[NH(Bn)·HCl,NOH] (a·HCl, a’·HCl) were prepared according to previous reports 
[62,63,66,67]. R- or S-limonene and isopentyl nitrite were reacted following the 
standard method described by Carman et al in 1977 [66]. R-limonene, S-limonene, [(6-
p-cymene)RuCl2]2, and cisplatin (cis-[PtCl2(NH3)2]) were purchased from Sigma-
Aldrich. Commercially available reagents were used without further purification. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 6 
Nuclear Magnetic Resonance (NMR) spectra were recorded on a Bruker 400 
Ultrashield. 
1
H and 
13
C chemical shifts are reported relative to tetramethylsilane. 
15
N 
chemical shifts are reported relative to liquid ammonia (25 ºC). Coupling constants J are 
given in Hertz. Elemental analysis was performed on a LECO CHNS 932 Analyzer at 
the Universidad de Alcalá or, alternatively, at the Universidad Autónoma de Madrid. 
Infrared (IR) spectra were recorded on IR Fourier Transform (FT) Perkin Elmer 
(Spectrum 2000) spectrophotometer on KBr pellets. The pH was measured in a 
HANNA HI208 pHmeter in distilled water solutions. Circular Dichroism (CD) spectra 
were recorded on a J-715 CD spectropolarimeter (Jasco, UK) at ambient temperature 
(297 K). The spectra were determined at a concentration of 0.5 mM in water using a 
quartz cuvette of 0.5 cm path length, scan speed of 20 nm·min
-1
, 0.1 nm band width, 0.5 
nm data pitch and 0.5 s of response time. Optical rotations of all the compounds 
solutions were recorded on a Perkin Elmer 341 polarimeter, using the sodium D line 
(589 nm) at ambient temperature (297 K) in a quartz cell of 1 dm path length. Specific 
optical rotation values were calculated according to the equation []24D = 100·obs/l·c 
[68]. Analytical balance and volumetric pipettes (2.0 mL) were used to prepare CHCl3 
solutions of the compounds at concentrations within a range of 7.50-7.80 g·mL
-1
.  Ultra-
violet visible (UV-vis) spectra were measured at room temperature on water solutions of 
the compounds with a Perkin Elmer Lambda 35 spectrophotometer.  
2.1.1. SRuSN-(1R,4S)-[(
6
-p-cymene)Ru{kNH(Bn),kNOH}Cl]Cl (1a’). An analogous 
procedure to that described before for the synthesis of 1a [61,67]  was used. A 
dichloromethane (10 mL) solution of a’ (0.27 g, 0.98 mmol) and [(6-p-cymene)RuCl2]2 
(0.30 g, 0.49 mmol) was stirred for 30 min at room temperature. Evaporation of the 
solvent affords a yellow solid. Yield: 0.25 g (83%). []23D (deg·dm
-1
·dL·g
-1
) -94.2 ± 1.2 
(1a’ at c = 0.764 g·dL-1, obs = -0.720 deg), +94.3 ± 1.2 (1a at c = 0.764 g·mL
-1
, obs = 
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+0.721 deg). Solubility in H2O at 24 ºC (mM): 28 ± 4 mM. Value of pH ([9.0 mM]) in 
H2O at 24 ºC: 4.70. Analytical and spectroscopic data of the compound are identical to 
those reported before [61,67] (see Supplementary data). Anal. Calcd for 
C27H38Cl2N2ORu: C, 56.05; H, 6.62; N, 4.84; Found: C, 55.78; H, 6.57; N, 5.15. IR 
(KBrmax/cm-1): 3400-3040 (NH/NOH), 1643, 1600 (C=N). UV-vis (0.1 mM in 
H2O): λmax (ε): 246 (8111), 324 (1577), 422 (631). Since NMR spectra of the 
compound in chloroform-d1 changed dramatically within a concentration range of ca. 5-
62 mM, full characterization was carried out in methanol-d4 [61]. 
1
H NMR (plus HSQC, 
plus HMBC, 400.1 MHz, 293 K, methanol-d4):  7.45 (m, overlapped, C6H5), 5.85, 
5.84, 5.46, 5.33 (all d, each 1 H, JHH = 3, p-cymene-C6H4), 4.79 (s, 1H, =CH2), 4.72 
(second order system, 2H, -CH2), 4.60 (s, 1H, =CH2), 4.02 (br, 1H, NH), 3.60 (d, 1H, 
JHH = 16, -CH2
3
), 2.53 (overlapped, 3H, p-cymene-CHMe2 + -CH
4
 + -CH2
3
), 2.14 (m, 
1H, -CH2
6
), 1.99 (s, 3H, p-cymene-CH3), 1.83 (m, 2H, -CH2
5
), 1.66, 1.65 (both s, each 
3H, CqCH3 +CH3-C=), 1.39 (m, 1H, -CH2
6
), 1.22, 1.02 (both d, each 3H, JHH = 6, p-
cymene-CH(CH3)2). 
13
C NMR (plus Attached Proton Test (APT), plus gradient 
Heteronuclear Single Quantum Coherence (gHSQC), plus Heteronuclear Multiple Bond 
Correlation (HMBC), 100.6 MHz, 293 K, methanol-d4):  170.8 (−, Cq=N), 145.9 (−, 
=Cq-Me), 137.1 (−,Cipso -C6H5), 130.1, 129.5, 129.4 (all +, -C6H5), 113.2 (−, =CH2), 
108.9, 98.8 (both −, Cipso-p-cymene), 87.5, 84.8, 83.3, 83.2 (all +, p-cymene:C6H4), 70.5 
(−, Cq-NH), 55.9 (−, -CH2Ph), 39.4 (+, -CH
4), 35.4 (−, -CH2
6
), 32.5 (+, p-cymene-
CHMe2), 29.1 (−, -CH2
3), 25.1 (−, -CH2
5
), 23.9 (+, p-cymene-CH(CH3)2), 22.3 (+, CH3-
CNH), 20.8 (+, p-cymene-CH(CH3)2), 20.7 (+, CH3-C=), 18.4 (+, CH3-:p-cymene).
 15
N 
NMR (gHMBC, 40.5 MHz, 293 K, chloroform-d1):  272.0 (C=N), 50.4 (NHBn).  
15
N 
NMR (gHMBC, 40.5 MHz, 293 K, methanol-d4):  266.7 (C=N), 50.0 (NHBn).  
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2.1.2. 1H NMR experiments at physiological pH. Phosphate buffered saline solution 
(PBS) was prepared according to Cold Spring Harbor Protocols 
(http://cshprotocols.cshlp.org/content/2006/1/pdb.rec8247) using NaCl, KCl, Na2HPO4 
and KH2PO4 in D2O. Adjustment of pD (pD = pH* + 0.4, where pH* = pHmeter 
reading in D2O) was carried out using a solution of DCl (0.01M) or NaOD (0.01M) in 
D2O, with the help of a HANNA HI208 pHmeter..  
2.2. Single-crystal X-ray structure determination  
Yellow crystals of the pure enantiomer 1a’·2CHCl3 were grown from a hexane-
chloroform solution. The crystals were removed from the vial and covered with a layer 
of a viscous perfluoropolyether. A suitable crystal was selected with the aid of a 
microscope, mounted on a cryo-loop, and placed in the low-temperature nitrogen 
stream of the diffractometer. The intensity data sets were collected at 200 K on a 
Bruker-Nonius Kappa CCD diffractometer equipped with an Oxford Cryostream 700 
unit. The molybdenum radiation ( = 0.71073) was used, graphite monochromated, 
and enhanced with an MIRACOL collimator.  
The structure was solved, using WINGX package [69], by intrinsic phasing methods 
(SHELXT) [70], and refined by least-squares against F2 (SHELXL-2014/7) [70]. 
Crystals of 1a’ contained two independent molecules in the asymmetric unit, but there 
were no significant differences between them. 1a’ crystallized with two molecules of 
chloroform per ionic pair. All non-hydrogen atoms were anisotropically refined, 
whereas the hydrogen atoms were included, positioned geometrically, and refined by 
using a riding model. DELU and SIMU restraints were used for the aromatic ring 
C(32)-C(37) of a benzyl group. Crystal data for 1a’·2CHCl3: (C29H40Cl8N2ORu), FW = 
817.30, Monoclinic, space group P21, crystal dimensions (mm
3) 0.31 x 0.13 x 0.12, a = 
8.865(2), b = 21.916(2),  = 90.49(1), c = 18.183(2) Å, V = 3532.7(8) Å3, Z = 4, calcd = 
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1.537 g cm–3,  = 1.075 mm–1, F(000) = 1664,  range = 3.00 to 25.24 deg, no. of rflns 
collected = 66843, no. of indep rflns / Rint = 12759 / 0.174, no. of data / restraints / 
params = 12759 / 49 / 751, R1 / wR2 (I>2(I)) = 0.071 / 0.114, R1 / wR2 (all data) = 
0.132 / 0.134, GOF (on F2) = 1.085, Absolute structure parameter = –0.06(2). Final 
difference Fourier maps did not show peaks higher than 0.699 nor deeper than –0.588 
eÅ–3. CCDC-1572919 contains the supplementary crystallographic data for this paper. 
These data can be obtained free of charge from The Cambridge Crystallographic Data 
Centre via www.ccdc.cam.ac.uk/structures. 
2.3. Cell culture, cytotoxicity assays and cell death analysis 
2.3.1. Cell culture 
The androgen-unresponsive prostate cancer cell line PC-3 was obtained from the 
American Type Culture Collection (Manassas, VA) and may be related to recurrent 
prostate cancers that have achieved androgen independence. All culture media were 
supplemented with 1% penicillin/streptomycin/amphoterycin B (Life Technologies, 
Barcelona, Spain). The culture was performed in a humidified 5% CO2 environment at 
37 °C. After the cells reached 70–80% confluence, they were washed with PBS, 
detached with 0.25% trypsin/0.2% ethylendiaminetetraacetic acid (EDTA) and seeded 
at 30,000–40,000 cells·cm-2. The culture medium was changed every 3 days. A-549 
(lung carcinoma) cells were maintained in high glucose DMEM (Dulbecco´s Modified 
Eagle´s Medium) supplemented with 5% fetal bovine serum (FBS), 200 U·mL
-1
 
penicillin, 100 μg·mL-1 streptomycin and 2 mM L-glutamine. MIA PaCa-2 (pancreas 
carcinoma), HCT-116 (colorectal carcinoma), HeLa (cervical cancer), Jurkat (leukemic 
cancer), Jurkat-pLVTHM (obtained by transfection with nonspecific short hairpin 
ribonucleic acid (shRNA)) and Jurkat-shBak (obtained by ribonucleic acid interference 
(RNAi) of Bak) cells were maintained in Roswell Park Memorial Institute (RPMI) 1640 
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medium supplemented with 5% FBS, 200 U·mL
-1
 penicillin, 100 μg·mL-1 streptomycin 
and 2 mM L-glutamine. Cultures were maintained in a humidified atmosphere of 95% 
air:5% CO2 at 37 °C. Adherent cells were allowed to attach for 24 h prior to addition of 
compounds. 
2.3.2. MTT Toxicity Assays 
For toxicity assays, cells (5 × 10
4
 for Jurkat cells and 10
4
 for adherent cell lines) were 
seeded in flat-bottom 96-well plates (100 μL/well) in complete medium. Adherent cells 
were allowed to attach for 24 h prior to addition of cisplatin or tested compounds. Stock 
solutions of ammonium-oxime pro-ligands were freshly prepared in 1% of dimethyl 
sulfoxide (DMSO) in water, while cisplatin and p-cymene ruthenium compounds were 
dissolved in water. The stock solutions were then diluted in complete medium and used 
for sequential dilutions to desired concentrations. The final concentration of DMSO in 
the cell culture medium did not exceed 0.1%. Control groups with and without DMSO 
(0.1%) were included in the assays. Compounds were then added at different 
concentrations in quadruplicate. Cells were incubated with compounds for 24 h, and 
then cell proliferation was determined by a modification of the MTT-reduction method. 
Briefly, 10 μL/well of [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] 
(MTT) (5 mg·mL
-1
 in PBS) was added, and plates were incubated for 1−3 h at 37 °C. 
Finally, formazan crystals were dissolved by adding 100 μL/well iso-propanol (0.05 M 
HCl) and gently shaking. The optical density was measured at 550 nm using a 96-well 
multi-scanner auto-reader (Enzyme-Linked Inmuno Sorbent Assay, ELISA).  
2.3.3. Cell Death Analysis 
Apoptosis hallmarks of cells treated with the metal compounds were analyzed by 
measuring the exposure of phosphatidylserine. Cells were treated with the compound at 
2.5 µM for 24 h and phosphatidylserine exposure was quantified by labeling cells with 
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annexin V-DY634 (Invitrogen). Annexin V was added at a concentration of 0.5 μg·mL-1 
in Annexin Binding Buffer (ABB), and cells were incubated at room temperature for 15 
min. Finally, cells were diluted to 500 µL with ABB to be analyzed by flow cytometry 
(FACScan, BD Bioscience, Spain). Cell morphology after treatment with metal 
compounds was evaluated through optical microscopy. 
2.4. DNA interaction studies 
2.4.1. Equilibrium Dialysis 
Duplex DNA from CT (Deoxyribonucleic acid, Activated, Type XV) was directly 
purchased from Sigma Aldrich and used as provided. Duplex-forming oligonucleotides 
ds17-1 (5'-CCA GTT CGT AGT AAC CC-3') and ds17-2 (5'-GGG TTA CTA CGA 
ACT GG-3') were acquired High Performance Liquid Chromatography (HPLC) purified 
and desalted from Integrated DNA Technologies (IDT). Dialysis membranes 
(Spectra/Por® molecular porous membrane tubing MWCO: 3.5–5.0 kDa; 6.4 mm 
diameter) were purchased from Spectrum Laboratories Inc. Aqueous solutions of 
surfactant sodium dodecyl sulfate (10%) were purchased from Sigma Aldrich. The 
buffer employed in this experiment was 10 mM phosphate buffer NaH2PO4/Na2HPO4, 
pH = 7.2, with either 10 mM or 100 mM NaCl. The solutions of DNA were prepared in 
the working phosphate buffer at 75 M monomeric unit (m.u.) concentrations, in base 
pairs. For the preparation of the short oligonucleotide solution, an annealing step was 
needed, with heating at 90 °C for 10 min and then gradually cooling to 25 °C during 3 
h. The solutions were left at 4 °C overnight.  
Dialysis bags, previously washed with milli-Q water, were filled with 75 M (m.u.) 
of DNA duplex (200 L each bag) and placed in a beaker containing 225 mL of ca. 20 
M solution of the tested compound. The beaker was covered with parafilm and 
aluminium foil and allowed to equilibrate during 24 h at room temperature. Experiments 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 12 
were run, at least, in triplicate. Once the dialysis process had been completed, the 
solutions from each dialysis bag were transferred to Eppendorf tubes. The content of 
each bag was then mixed with an aqueous detergent solution (10%) to reach a 1% 
concentration (v/v) of sodium dodecyl sulfate (SDS). The concentrations of free 
compound in the dialysate solution and compound in the dialysis bags were determined 
by absorbance measurements using the extinction coefficients of the metal complexes 
(determined in the presence and absence of the detergent) and apparent association 
constants were calculated [71]. 
2.4.2. DNA FRET melting assay 
The DNA melting assay was performed on a quantitative PCR kit ABI PRISM® 7000 
Sequence Detection System (Applied Biosystems) in a 96-well plate format (96-Well 
Optical MicroAmp® Reaction Plate, Applied Biosystems, Life Technologies 
Corporation). The oligonucleotide sequence employed in this experiment, F10T (5'-
FAM-AGC TAT TA TA /sp18/ TA TA GCT ATA-TAMRA-3') was produced, HPLC-
purified and desalted by IDT. FAM is 6-carboxyfluorescein and TAMRA is 
carboxytetramethylrhodamine. The buffer system used in this experiment was: 10 mM 
sodium cacodylate, 100 mM LiCl, (pH = 7.3). First, the duplex-forming oligonucleotide 
was dissolved in water (Biotechnology Performance Certified, BPC grade) and a 50 M 
stock solution was prepared, which was then diluted to 0.5 M.  Then, the diluted DNA 
solution was mixed with the working buffer (2x) and water (BPC grade). The DNA 
solution was heated at 90 °C for 10 min, cooled down slowly for 3 h and left at 4 ºC 
overnight. Compounds to be tested were dissolved in water and approximately 1 mM 
stock solutions were prepared. The exact concentrations were checked by UV-vis. Stock 
solutions were then diluted with buffer to obtain 50 M solutions of each compound. In 
a 96-well microplate, DNA solutions were mixed with solutions of tested compound 
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and buffer to reach a total volume of 50 L with a F10T concentration of 0.2 M and a 
compound concentration ranging between 1 and 10 M. 
The experimental protocol consisted of an incubation for 5 min at 24 °C, followed by 
a temperature ramp with heating rate 1 °C/min. Fluorescence values corresponding to 
the fluorophore FAM at wavelength of 516 nm (after excitation at 492 nm) were 
collected at each degree of temperature. Afterwards, the fluorescence data were 
normalized, plotted against temperature (ºC) at each compound concentration, and 
melting temperatures (Tm) values were determined. 
2.4.3. Viscometric titrations 
Duplex DNA from CT (Deoxyribonucleic acid, Activated, Type XV) was purchased 
from Sigma Aldrich and used as provided. The buffer employed in this experiment was 
10 mM phosphate buffer NaH2PO4/Na2HPO4, pH = 7.2. The viscosimetric 
measurements were performed in a Visco System AVS 470 at 25.00 ± 0.01 ºC, using a 
microUbbelohde (K = 0.01) capillary viscometer. 6 mL of DNA solution (0.4 mM in 
nucleotides) in phosphate buffer were equilibrated for 20 min at 25.00 ºC and then 20 
flow times were registered. Small aliquots (30–50 L) of solutions of metal complexes 
(1.6–2.3 mM) were added to the same DNA solution. Before each flow time 
registration, the solutions were equilibrated for 20 min to 25.00 ºC and then 20 flow 
times were measured. With the averaged time of the different flow time measurements 
and the viscometer constant, the viscosities () for each point were calculated. The 
viscosity results were plotted as (
1/3
, where represents the DNA solution 
viscosity in the absence of the ligand, versus (r), representing the ratio [ligand]/[DNA].   
2.5. In vivo Test  
2.5.1. Animals, xenografts, and processing of tumors 
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Athymic male nude mice (nu/nu) 4 weeks old were obtained from Harlan (Oxon, 
UK) and maintained in microisolator units on a standard sterilizable diet. Mice were 
housed under humidity- and temperature-controlled conditions, and the light/dark cycle 
was set at 12 h intervals. Experimental procedures are carried out according to Spanish 
Law 32/2007, Spanish Royal Decree 1201/2005, European Directive 609/86/CEE and 
European Convention of Council of Europe ETS 123. PC-3 cells were incubated in the 
absence or presence of 2.5 M 1a for 24 h. Then, they were washed with PBS, detached 
with 25% trypsin/0.2% EDTA, centrifuged at 400 × g, and re-suspended in fresh 
medium at 1 × 108 cells/mL. The cell suspension was mixed with Matrigel® (BD 
Bioscience) synthetic basement membrane (1:1, v/v) and then injected subcutaneously 
into the right flank of nude mice (5 × 106 cells/mouse). Ten animals were used per 
group. Tumors were harvested after sacrifice at 6 weeks of subcutaneous cell injection. 
Animals were divided into two groups: group 1, control; group 2, 1a. Tumor volume 
(mm3) = (length × width × height × 0.5236) was assessed every three or four days. The 
experiment was ended on day 43. All mice were euthanized by cervical dislocation upon 
study completion and tumors collected postmortem. Tumor specimens were frozen in 
liquid nitrogen and maintained at −80°C for further experiments.  
2.5.2. Isolation of tissue lysates 
Tumor specimens were homogenized in 50 mM Tris–HCl (pH 7.6) containing 1% 
Triton X-100, 200 mM NaCl, 10 mM CaCl2, 5 μg·mL
-1 aprotinin, 5 μg·mL-1 leupeptin, 
and 5 μg·mL-1 pepstatin and then rotated for 30 min in a cold room. The extract was 
cleared by centrifugation at 15,000 × g for 30 min at 4 °C.  
2.5.3. Determination of Vascular Endothelial Growth Factor (VEGF) 
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VEGF levels were determined in tumor homogenates (25 μg) by ELISA, (human 
VEGF DuoSet, R&D Systems, Madrid, Spain) according to the manufacturer's 
instructions. Data were normalized to the protein concentration in each sample. Gelatin 
zymography: The tumor homogenates were analyzed by zymography using 10% sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE) containing 0.1% (w/v) 
gelatin (Sigma, Alcobendas, Spain) as the substrate. Each lane was loaded with a 3 g 
protein and subjected to electrophoresis at 4 ºC. Gels were washed twice in 50 mM Tris 
(tris(hydroxymethyl)aminomethane, pH 7.4) containing 2.5% (v/v) Triton X-100 for 1 
h, followed by two 10-min rinses in 50 mM Tris (pH 7.4). After SDS removal, gels 
were incubated overnight in 50 mM Tris (pH 7.5) containing 10 mM CaCl2, 0.15 M 
NaCl, 0.1% (v/v) Triton X-100, and 0.02% sodium azide at 37 ºC under constant 
shaking. Then, gels were stained with 0.25% Coomasie Brilliant Blue R-250 (Sigma) 
and distained in 7.5% acetic acid with 20% methanol. MMP-2 (metaloproteinase-2) and 
MMP-9 (metaloproteinase-9) activities were semiquantitatively determined by 
densitometry.  
2.5.4. Data analysis 
Results were subjected to computer-assisted statistical analysis using One-Way 
Analysis of Variance ANOVA, Bonferroni´s post-test, and Student´s t-test. Data are 
shown as the means of individual experiments and presented as the mean ± SD 
(Standard deviation). Differences of P < 0.05 were considered to be significantly 
different from the controls. 
3. Results and Discussion 
3.1. Synthesis and characterization of metal compounds 
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Synthesis of the novel Ru(II) compound was carried out analogously to that of 
previously described enantiomer 1a [61,67]. Thus, the reaction of dimer [(6-p-
cymene)RuCl2]2 with amino-oxime derivative (1R,4S)-{NOH,(Bn)NH} (a’), proceeds 
also stereoselectively to afford enantiomerically pure SRuSN-(1R,4S)-[(
6
-p-
cymene)Ru{ĸNH(Bn),ĸNOH}Cl]Cl (1a’) (Fig. 2).  
FIGURE 2 
Since Ru(II) compound 1a’ is a chiral-at-metal complex with a new stereogenic centre 
at the amino ligand, four different diastereomers distinguishable by NMR spectroscopy 
could be formed, namely RRuSN-(1R,4S)-, RRuRN-(1R,4S)-, SRuSN-(1R,4S)- or SRuRN-
(1R,4S)-1a’. 1H and 13C NMR spectra of the solid showed the existence of only one 
diastereomer in solution, which has been fully characterized as SRuSN-(1R,4S)-[(
6
-p-
cymene)Ru{ĸNH(Bn),ĸNOH}Cl]Cl (1a’). Epimerization [22,60,72,73] was never 
observed in chloroform-d1, acetone-d6, methanol-d4, water-d2 or PBS solutions over 
time (up to 72 h), within a temperature range of 10-60 ºC (see Supplementary data, Fig. 
S4, S5, S6, S9), suggesting a preferred mode of the ligand chelation [74-79]. Similar 
results had previously been observed by us during the synthesis and characterization of 
derivative 1a [61]. 
Analytical and spectroscopic data of the novel compound 1a’ are identical to those 
reported before for 1a [61,67] (see Experimental Section and Fig. S3-S9, S11). The UV-
vis spectrum of 1a or 1a’ (see Supplementary data, Fig S11) shows two absorption 
bands at 324 and 422 nm, followed by a more intense band at 246 nm. Both derivatives 
gave complementary CD spectra (Fig. 3), with opposite Cotton effects at 246, 284, 320 
and 380 nm. Although CD cannot give information on the absolute configuration, these 
results confirm that the molecular structures of 1a and 1a’ are mirror images [20].  
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FIGURE 3 
Calculated data of specific optical rotation in chloroform solution for the pro-ligands 
and metal compounds ([]23D (deg·dm
-1
·dL·g
-1
) = +130 ± 1.3 a, -127 ± 1.3 a’, +94.3 ± 
1.21a, -94.2 ± 1.2 1a’) evidence again the enantiomeric relationship of the 
stereoisomers. Furthermore, absolute configuration of compound 1a’ has been 
confirmed through X-ray structure determination (Fig. 4, Table S1, S2, Fig. S13). X-ray 
molecular structure of 1a was reported elsewhere [67].  
The solid-state structure of 1a’ contains two independent molecules in the asymmetric 
unit, with no substantial differences between them (Table S2), and with the same 
absolute configuration of the four chiral centers. An ORTEP diagram of one of these 
independent molecules is shown in Fig. 4. The compound adopts the expected piano-
stool geometry, with the ruthenium atom bound to the arene ligand through 6 bonding. 
All the bond lengths and angles are in agreement with analogous oxime ruthenium 
compounds previously reported [56,57,67,80].  
FIGURE 4 
 
3.2. In vitro cell studies  
 3.2.1. Anti-proliferative studies 
Chiral compound 1a has already shown their promising anticancer properties on the 
human prostate cancer cell line PC-3 [61].  
Epimerization at the Ru(II) center of 1a or 1a’ after a 72 h incubation period under 
physiologically relevant conditions does not occur (Fig. S9). This fact suggests that the 
complexes are stable enough to allow further investigations into the effect of chirality 
on their anti-proliferative effectiveness. Thus, in order to compare and evaluate the 
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versatility of the different enantiomers, the cytotoxic activity of pro-ligands a·HCl and 
a’·HCl and metal compounds [(η6-p-cymene)RuCl2]2, 1a and 1a’ was now assessed on 
a wide variety of human cancer cell lines, i.e. prostate PC-3, lung A-549, pancreas MIA 
PaCa-2, colon HCT-116, leukemia Jurkat-T, and cervical HeLa. The in vitro effect of 
the compounds on cytotoxicity was evaluated by monitoring their ability to inhibit cell 
growth using the MTT assay after 24 h of incubation time.  
While pro-ligands a·HCl, a’·HCl and metal compound [(η6-p-cymene)RuCl2]2 are 
poorly cytotoxic in all tested cell lines (IC50 > 150 μM under this experimental 
conditions), both enantiomers 1a and 1a’ are versatile cytotoxic agents, with IC50 values 
ranging from 4.0 to 18.4 µM in the different cell lines tested (Table 1).  
TABLE 1 
These ruthenium compounds showed better cytotoxic profiles than those found for 
cisplatin (from 2 to 12 times more active), with only minor differences observed 
between the two enantiomers.  
Our compound, with an IC50 value of 7.2 µM, is as cytotoxic in lung cancer A-549 cells 
as the promising iminophosphorane Ru(II) compound [(6-p-cymene)Ru(Ph3P=NCO-2-
NC5H4-ĸN,O)Cl]Cl (IC50 = 9.5 µM, 24 h) [81]. 1a is also as active as Sadler’s 
compound [(6-C6H5Ph)Ru(en)Cl][PF6] (RM175, en = ethylenediamine) in colon 
carcinoma HCT-116 cells (IC50 = 16 µM) [82]. A highly efficient ruthenium complex 
against colorectal cancer cells is the cyclopentadienyl Ru(II) carbohydrate containing 
compound described by Florindo et al (IC50 values of 0.45 µM in HCT-116 cells, 72 h, 
as potent as oxaliplatin ([Pt(oxalate)(R,R-1,2-diaminocyclohexane)]), the first choice of 
treatment for colon carcinoma patients in advanced stages [83]). Other promising Ru(II) 
compounds are the cyclopentadienyl ciprofloxacin derivate reported by Ude et al [84], 
with IC50 values after 24 h of exposure to the drug as low as 0.25 µM (A-549), 1.33 
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(HCT-116) and 1.46 (PC-3) and the 2,2’-bypyridine derivative [(5-
C5H5)Ru(bypy)(PPh3)][CF3SO3] (TM34, IC50 = 0.54 in PC-3 cells, 72 h) [85].  
 3.2.2. Mechanism of cell death 
The mechanism of cell death induced by these chiral oxime compounds was analyzed 
in A-549 and Jurkat cell lines.  
Cell morphology evaluation of A-549 cells indicated that ruthenium derivatives 1a 
and 1a’ induced apoptotic cell death, characterized by condensed nuclei and membrane 
blebbing. Cis-platin was included in the experiment as a positive control, since 
cisplatin-treated cells show typical apoptotic morphology (Fig. S14). 
We analyzed the implication of mitochondria in the toxicity of metal compounds. In 
the intrinsic pathway of apoptosis, initiated by cell damage, the pro-apoptotic Bax and 
Bak proteins are required for the release of cytochrome C from mitochondria. Thus, 
cells lacking these two proteins cannot activate the intrinsic pathway and are usually 
resistant to chemotherapy drugs. Jurkat cells do not express Bax, due to a genetic 
deletion, and the subline Jurkat-shBak cells, obtained by RNAi of Bak [86], are 
deficient in both proteins. Thus, Jurkat-shBak cell line constitutes a model of human 
leukemia cells deficient in the intrinsic (mitochondrial) pathway of apoptosis. A cell 
line transfected with a nonspecific shRNA (named Jurkat pLVTHM) was used as a 
control in these experiments, to discard any unspecific effect due to the transfection and 
selection process necessary to generate the Jurkat shBak subline. 
A comparison between the effect of 1a and starting materials on Jurkat-T cell 
apoptosis has been performed. As shown in Fig. 5, 1a (2.5 µM), but not the starting 
materials a·HCl (5 µM), [(6-p-cymene)RuCl2]2 (2,5 µM), or the combined dose of 
both, induced cell death in a high percentage of Jurkat control (pLVTHM) cells but not 
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in Jurkat-shBak cells, suggesting that, 1a induced cell death through the intrinsic 
pathway at these concentrations.  
FIGURE 5 
Dose-response experiments using the MTT assay (Fig. S15) showed that both 
enantiomers 1a and 1a’ exhibited toxicity at concentrations higher than 10 µM in both 
Jurkat cell lines, suggesting that Bax/Bak-independent cell death mechanisms can be 
also activated by these compounds. DNA interaction analysis described below revealed 
that the two enantiomers partially bind to DNA. In a cellular context, this interaction 
with DNA could likely induce DNA damage and activation of the intrinsic pathway of 
apoptosis. Interestingly, at higher doses both compounds can circumvent the lack of 
Bax and Bak, indicating that apoptosis-resistant tumors that are commonly resistant to 
chemotherapy could be sensitive to them through alternative cell death mechanisms.  
3.3. DNA binding  
Having established the antitumor properties of metal compounds 1a and 1a’, we then 
set out to study their interactions with DNA as a potential cellular target, as DNA 
recognition might partially account for the observed biological activity. With this in 
mind, we have studied DNA binding by using equilibrium dialysis, fluorescence-based 
DNA melting experiments and DNA viscometric titrations. 
Dialysis experiments, based on the fundamental thermodynamic principle of 
equilibrium dialysis [71,87], were performed to determine apparent binding constants 
between DNA and the metal compounds. As the DNA targets, we selected CT DNA 
and a short oligonucleotide duplex of known sequence (ds17,17 bp).  
The results obtained for compounds 1a and 1a’ using two different DNA sequences 
are summarized in Table 2. Experiments were run based on adaptation of the protocol 
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described by Chaires [71], with some modifications as described in the Experimental 
section.  
TABLE 2 
Table 2 shows that these compounds have a modest to good binding affinity for 
duplex DNA, with apparent association constants in the order of 10
4 
M
-1
. In general, no 
significant differences in DNA affinity were found between the two enantiomers, 
although 1a showed a two-fold better binding affinity in the case of CT DNA, whereas 
1a’ displayed a better affinity towards the particular sequence of oligonucleotide ds17.   
As part of our study on DNA interactions we were interested in determining the effect 
that these compounds may exert on the DNA denaturing temperature, Tm. We utilized a 
variable-temperature (FRET-melting) assay, an experiment that reduces DNA 
consumption while assessing a wide range of tested compound concentrations, it can be 
adapted to a high-throughput fashion, and it has been extensively used in the last years 
to determine the degree of thermal stabilization of different DNA structures in the 
presence of potential ligands [88]. Thus, FRET experiments were used to establish 
whether either the precursor ligands a·HCl and a’·HCl or the metal complexes 1a and 
1a’ were able to thermally stabilize duplex DNA structures.  
In these experiments, a 10-bp oligonucleotide (F10T) labeled with two fluorophores, 
FAM at its 5' end and TAMRA at the 3' end, was selected [89]. If the metal complex 
binds to DNA affecting the stability of the helix, changes in the value of DNA Tm 
should be expected. Stabilization of duplex DNA usually results in increased values of 
Tm.  
Metal complexes 1a and 1a’ were analysed for their ability to affect duplex DNA 
melting in the 1-10 μM concentration range. However, under these conditions, these 
complexes did not produce a significant change in the DNA melting temperature 
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(Tm= -2 ºC at 10 µM, Fig S16). Furthermore, none of the enantiomers of the precursor 
ligands, a·HCl or a’·HCl, showed DNA stabilization. These results are in good 
agreement with previous reported DNA melting experiments on CT DNA with the 
metal compound 1a [61] and seem to suggest that the compounds may interact with 
DNA in an external, mainly electrostatic fashion or through partial recognition of the 
DNA grooves.   
Finally, DNA viscometric titrations were carried out as it is well known that viscosity 
measurements can provide a simple way to discriminate between the different binding 
modes of potential DNA ligands (especially non-covalent, such as intercalation versus 
groove or external binding) [90]. According to the theory of Cohen and Eisenberg [91], 
from gradual titration of DNA solutions with the compounds of interest, linear plots of 
the cubed root of the relative DNA viscosity (/o)
1/3
 versus the molar ratio of bound 
ligand to DNA nucleotide (r) can be obtained. The slope values in these plots correlate 
well with the DNA-ligand binding modes. Groove binding compounds normally display 
a slope close to 0.0, whereas classical mono-intercalants result in a slope close to 1.0 
[90,91]. Experimentally, the slopes associated with prototype minor-groove binders, 
such as pentamidine, range from -0.3 to 0.2 [92], while those of classical mono-
intercalators, such ethidium bromide, can vary from 0.80 to 1.50 [92-94].  
Complexes 1a and 1a’ showed a linear ()
1/3
 versus r correlation in the typical r 
range used in these experiments (Fig. 6) and produced some modification of the 
viscosity of the DNA solution at increasing concentrations, with negative slope values 
of -0.36 in the case of the enantiomer 1a and -0.38 for the 1a’ counterpart.  
FIGURE 6 
It is evident from these results that these metal complexes do not interact with double 
stranded DNA by inserting the aromatic ring between the base pairs, thus a classical 
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intercalating interaction can be directly ruled out. This is no surprising taking into 
account the relative small surface of the arene ring. The viscosity slope values fall 
within or are close to the experimental values of typical groove binding ligands, but the 
negative slope may be also suggestive of a slight shortening of the DNA double helix, 
producing an overall effect of DNA compaction. It is known that metal complexes that 
bind DNA by a partial or non-classical intercalation (binding in the grooves or in the 
sugar-phosphate backbone) may decrease the DNA contour length by bending or 
kinking the DNA helix [95-97]. Although further studies should be carried out to 
determine the precise nature of this DNA interaction, these experiments suggest that 
DNA could act as a potential cellular target for these metal complexes and their 
interaction might partially contribute to the observed biological effect. 
 
3.4. In vivo analysis 
 3.4.1. Effect of treatment of PC-3 cells with compound 1a on the growth of 
xenografted PC-3 human prostate cancer cells 
PC-3 cells were incubated in the absence or presence of 1a for 24 h and then injected 
subcutaneously into the right flank of nude mice. Ten animals were used per group. 
Final tumor volume measurements revealed that the tumor growth was significantly 
inhibited by 45% (1,719 ± 206 mm
3
) in 1a group after 43 days, as compared with those 
from control group which measured 961 ± 160 mm
3
 (Fig. S17, Table 3). Furthermore, 
the mean tumor weight was significantly reduced to 1,008 ± 103 mg compared with that 
in the control group (1,633 ± 153 mg), corresponding to a decrease of about 39% (Table 
3). The Tumour Doubling Time (TDT) in the 1a group was extended and was 
significantly different (P < 0.05) from doubling times in the control group (Table 3). 
TABLE 3 
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Metal compounds which have demonstrated to be effective in decreasing tumor 
growth in an in vivo assay of nude mice bearing PC-3 tumor xenografts are the water 
soluble analogue of oxaliplatin, [Pt(S,S-1,2-
diaminocyclohexane)(phen)]Cl2·1.5H2O·0.5HCl [98] and the promising Tacke’s 
compound Titanocene-Y (bis-[(p-methoxybenzyl)cyclopentadienyl]titanium(IV) 
dichloride) [99].   
 3.4.2. Effect of treatment of PC-3 cells with 1a on the expression of the activity 
of metalloproteinases-9 and -2 and on the expression of VEGF of xenografted PC-3 
human prostate cancer cells 
A significant correlation between the expression of MMP-9, MMP-2, and VEGF has 
been observed in cell lines as well as in tissue specimens of prostate cancer [100,101]. 
Overactive MMPs contribute to an almost complete loss of the basement membrane 
proteins in most cancers including prostate carcinomas [102]. Moreover, it has been 
described that the invasion and the motility of prostate tumor cells were increased by 
MMP-2 and MMP-9 [103]. Several studies have shown that VEGF is closely correlated 
with neovascularization and prognosis in many solid tumors. Thus, an increased 
expression of VEGF in prostate cancer [104], as well as a positive correlation between 
VEGF and Gleason score, tumor grade, and microvessel density, has been observed 
[104-107]. The successful antimetastatic NAMI-A compound was found to inhibit 
angiogenesis induced by VEGF in vivo [108]. 
The activity of both gelatinases was assessed by zymography assays (Fig. 7A). Latent 
forms of MMP-9 (95 kDa) and MMP-2 (72 kDa) were detected. The densitometric 
analysis showed that the activities of the latent-MMP forms decreased significantly by 
45-49% (P < 0.001) in the 1a group as compared with the control group. In order to 
determine whether these tumors presented increased angiogenesis and its possible 
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variations, we checked VEGF165 levels by an ELISA assay. VEGF165 expression 
showed a significant decrease of 48% in 1a group (Fig. 7B).  
FIGURE 7 
In this first approach of establishing the potential therapeutic role of the compound 
1a, we exposed such a complex to androgen-independent prostate cancer cells and 
observed that it could affect the molecular machinery leading to a decrease in the 
tumorigenic capability of cells to represent the more aggressive form of prostatic 
adenocarcinoma or castration-resistant prostate cancers. In addition, levels of crucial 
molecules in the invasive phenotype as the main pro-angiogenic factor and the 
metaloproteinases -9 and -2 are found decreased.  
These results suggest that the efficacy of 1a as potential chemotherapeutic should be 
further explored. Additional experiments to determine the intraperitoneal efficacy of 1a 
on nude mice PC-3 xenografts has been scheduled for the near future. 
 
4. Conclusions 
The use of optically active amino-oxime ligands derived from natural products is a 
useful and inexpensive strategy to synthesize water soluble, enantiopure arene 
ruthenium compounds. The oxime-containing Ru(II) compounds evaluated, 1a and 1a’, 
have shown potent anticancer activities against a broad range of different cancer cell 
lines, with no significant differences between the two ruthenium enantiomers. Both 
compounds induced apoptotic cell death of A-549 cells while dose-dependent cell death 
mechanisms have been found in the Jurkat cell line. This last fact could be of interest in 
the treatment of apoptosis-resistant tumors that are commonly resistant to 
chemotherapy. Compound-DNA interactions have been investigated by a variety of 
techniques, leading to the conclusion that these metal complexes likely interact with 
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double stranded DNA by external electrostatic interactions and/or groove binding, while 
a classical intercalation into the double strand DNA can be ruled out. The efficacy of 1a 
in a preliminary in vivo assay of PC-3 xenografts in nude mice resulted in a promising 
inhibition of tumor growth by 45%. Analysis of tumor tissue showed a significant 
decrease of VEGF165 expression and of latent-MMP forms activities, proteins correlated 
with angiogenesis and invasion and motility of prostate tumor cells, respectively. These 
results, along with those described before regarding the ability of 1a to affect the 
metastatic phenotye of PC-3 cells in vitro, makes this oxime containing ruthenium 
compound a valuable choice for further investigations. 
 
Abbreviations  
A-549  Human cervical carcinoma cell line 
A-278  Human ovarian cancer cell line 
ABB Annexin Binding Buffer  
APT  Attached Proton Test 
Bn benzyl 
BPC grade Biotechnology Performance Certified grade 
Cisplatin cis-[PtCl2(NH3)2] 
CD Circular Dichroism 
COSY Correlation Spectroscopy 
Cq Quaternary carbon 
CT Calf Thymus  
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DMSO dimethylsulfoxide 
DMEM Dulbecco´s Modified Eagle´s Medium 
DNA Deoxyribonucleic acid 
EDTA ethylendiaminetetraacetic acid 
ELISA Enzyme-Linked Immuno Sorbent Assay  
FAM 6-carboxyfluorescein 
FBS Fetal Bovine Serum 
FRET Fluorescence Resonance Energy Transfer 
FT  Fourier Transform 
F10T 5'-FAM-AGC TAT TA TA /sp18/ TA TA GCT ATA-TAMRA-3' 
HCT-116 Human colorectal carcinoma cell line 
HeLa Human cervical cancer cell line 
HSQC Heteronuclear Single Quantum Coherence spectroscopy 
HMBC Heteronuclear Multiple Bond Correlation spectroscopy 
HPLC High Performance Liquid Chromatography 
IDT Integrated DNA Technologies 
IR Infrared 
Jurkat Human leukemic cancer cell line 
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Jurkat-pLVTHM Human leukemic cancer cell line obtained by transfection with 
 nonspecific short hairpin ribonucleic acid  
 Jurkat-shBak Human leukemic cancer cell line obtained by ribonucleic acid   
  interference of Bak 
MIA PaCa-2 Human Pancreas Carcinoma cell line 
MMP-2 metaloproteinase-2 
MMP-9 metaloproteinase-9 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide  
NMR  Nuclear magnetic resonance 
Oxaliplatin [Pt(oxalate)(R,R-1,2-diaminocyclohexane)]  
PAGE PolyAcrylamide Gel Electrophoresis 
PBS Phosphate buffered saline solution  
PC-3 Human androgen-independent prostate cancer cell line 
RM175 [(6-C6H5Ph)Ru(ethylendiamine)Cl][PF6] 
RNA ribonucleic acid 
RNAi ribonucleic acid interference 
RPMI Roswell Park Memorial Institute 
SDS Sodium Dodecyl Sulfate  
shRNA short hairpin ribonucleic acid 
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TAMRA Carboxytetramethylrhodamine.  
TDT Tumour Doubling Time 
Tm melting temperature 
TM34 [(5-C5H5)Ru(bypy)(PPh3)][CF3SO3]  
Titanocene-Y bis-[(p-methoxybenzyl)cyclopentadienyl]titanium(IV) dichloride 
UV-vis ultraviolet-visible 
VEGF Vascular Endothelial Growth Factor  
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for X-ray molecular structures of 1a’. 
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Figures and Tables 
 
 
Fig. 1. Optically active ruthenium compound containing an amino-oxime ligand derived 
from R-limonene. 
 
Fig. 2.  Synthesis of optically active amino-oxime ruthenium compounds. 
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Fig. 3. The CD spectra of enantiomers 1a and 1a’ in water solution. 
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Fig. 4. ORTEP drawing of compound 1a’ with 50% probability ellipsoids. Hydrogen 
bonded to carbon atoms have been omitted for clarity. Representative lengths (Å) and 
angles (deg): Ru(1)-Ct(1) 1.674; Ru(1)-Cl(1) 2.404(4); Ru(1)-N(11) 2.067(10); Ru(1)-
N(12) 2.173(10); N(11)-O(11) 1.381(13); Cl(1)-Ru(1)-N(11) 82.9(3); Cl(1)-Ru(1)-
N(12) 81.8(3); N(11)-Ru(1)-N(12) 75.8(4); Ru(1)-N(11)-O(11) 124.0(8); Ru(1)-N(11)-
C(21) 121.6(8); O(11)-N(11)-C(21) 114.4(10); Ru(1)-N(12)-C(22) 111.1(7); Ru(1)-
N(12)-C(31) 120.6(8); C(22)-N(12)-C(31) 112.7(10); (Ct(1) is the centroid of the 
C(11)-C(16) ring). 
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Table 1. IC50 values (µM) of metal compounds 1a and 1a’ in a variety of human cell 
lines.
a,b
  
 Metal compounds 
1a  1a’  Cisplatin 
PC-3 8.70 ± 1.50  14.0 ± 2.4 104.2 ± 8.1  
A-549 7.2 ± 1.5 9.1 ± 2.4 114.2 ± 9.1b 
MIA PaCa-2 9.7 ± 2.1 13.1 ± 2.6  76.5 ± 7.4b 
HCT-116 11.5 ± 2 .0 18.4 ± 1.8 34.9 ± 3.0b 
Jurkat-T 4.0 ± 0.7 4.7 ± 0.9 10.8 ± 1.2b 
HeLa 7.5 ± 1.2 6.7 ± 1.4 -- 
a
 Data are expressed as mean ± S.D. (n = 4)
       
b 
Values obtained with the same technique, cell lines and incubation times 
[32,45,81,109,110]. 
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Fig. 5. Comparison of the effect of [(6-p-cymene)RuCl2]2 + a·HCl, a·HCl and 1a on 
Jurkat-T cell apoptosis after 24 h of exposure ([RuCl2]2 = [(
6
-p-cymene)RuCl2]2). 
Table 2. DNA apparent association constants of ruthenium(II) compounds obtained by 
equilibrium dialysis
(a)
.  
 Compound 1a Compound 1a’ 
DNA Kapp (M
-1
)10
-4
  Kapp10
-4 
 
Calf Thymus (CT) 3.0 ± 0.3 1.5 ± 0.2 
ds17 sequence  2.4 ± 0.2 7.9 ± 0.3 
a
 Metal complex solutions were equilibrated with 75 µM of nucleic acid (in each 
dialysis bag) for 24 h at room temperature. UV-visible spectra were recorded after 
detergent addition and the concentrations of free and DNA-bound ligands determined. 
The competition dialysis data were used to calculate the 1a and 1a’ apparent association 
constants, given by the equation Kapp = Cb/(Cf)(Stotal-Cb), where Cb is the amount of 
metal complex bound, Cf is the free metal complex concentration and Stotal = 75 µM, 
in monomeric units. 
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Fig. 6. Viscometric titrations of Calf Thymus (CT) DNA and metal complexes 1a and 
1a’, at 25 ºC (10 mM sodium phosphate buffer, pH 7.2). 
 
Table 3. Effect of treatment of PC-3 cells with 1a on tumor weight, tumor burden and 
Tumor Doubling Time (TDT). Values are mean ± SE. *, P < 0.05 vs. control group. 
Groups  
 
Tumor weight, mg 
(% inhibition) 
Tumor burden, mg/g body weight 
(% inhibition) 
TDT, days 
(% increase) 
Control 
(n = 10)
a
  
1,633.8 ± 153 53.4 ± 5.6 8.68 ± 0.52 
1a  
(n = 10)
a
  
1,008 ± 103 
(39)* 
36.6 ± 3.1 
(68)* 
10.84 ± 0.58 
(25)* 
a
 (number of animals) 
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Fig. 7. Effect of treatment of PC-3 cells with compound 1a on A) the activity of 
metaloproteinase 9 and 2, and B) the expression of the proangiogenic factor VEGF165. 
Androgen-independent prostate cancer cells were incubated in the absence or presence 
of 1a (2.5 M) for 24 h. The cell suspension was mixed with Matrigel® and injected 
subcutaneously into the right flank of nude mice (5x10
6
 cells/mouse). Ten mice were 
used in each group. Pro-MMPs activities, as well as VEGF165 levels, were determined in 
tumor homogenates (25 μg) by ELISA and gelatin zymography. Data in each bar are the 
means ± SE. ***, P < 0.001 vs. control group. 
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Graphical abstract 
Easily accessible enantiopure ruthenium compounds RRuRN-(1S,4R)- and SRuSN-
(1R,4S)-[(6-p-cymene)Ru{ĸNH(Bn),ĸNOH}Cl]Cl (1a and 1a’) are reported. Both 
isomers exhibit potent cytotoxicities in a variety of different cancer cell lines. 
Evaluation of 1a in a preliminary in vivo assay of PC-3 xenografts in nude mice resulted 
in an inhibition of tumor growth by 45%.  
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Highlights  
 
 Synthesis of water soluble, amino-oxime containing arene Ru(II) enantiomers is 
reported.  
 Both enantiomers are more cytotoxic than cisplatin in all the cell lines tested. 
 No significant biological differences were found between the two enantiomers. 
 One of the enantiomers inhibited tumor growth of PC-3 xenografts in nude mice 
by 45%. 
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